

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

NOTICE OF BOARD MEETING

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, 26 March 2026 for the following purposes, among other things:

1. To consider and approve the audited consolidated financial statements of the Company and its subsidiaries (collectively the “**Group**”) for the year ended 31 December 2025 (the “**Annual Results**”);
2. To consider and approve the draft announcement of the Annual Results of the Group to be published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited;
3. To consider the payment of a final dividend, if any;
4. To consider matters related to the convening of the forthcoming annual general meeting of the Company; and
5. To consider and approve other matters, if any.

By Order of the Board
Consun Pharmaceutical Group Limited
AN Meng
Chairman

Hong Kong, 5 March 2026

As at the date of this announcement, the Board comprises Mr. An Meng and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua and Professor Zhu Quan as non-executive Directors; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.